Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Rossi

Showing results (561-570 of 724) with videos related to

Pageof 73
Sort By:
The Journal of Dermatological Treatment|April 30, 2020
Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trialsS Barbarot, A Wollenberg, J I Silverberg, et al.
Acta Dermato-Venereologica|May 27, 2021
Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant UseMette Deleuran, Danielle Marcoux, Marjolein S Bruin-Weller, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 4, 2025
Dupilumab improves quality of life assessed by the Quality of Life in Hand Eczema QuestionnaireEric L Simpson, Marie-Louise A Schuttelaar, Sonja Molin, et al.
Dermatology and Therapy|July 11, 2025
Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment ComparisonSonja Ständer, Andreas Pinter, Firas G Hougeir, et al.
Dermatology and Therapy|December 29, 2025
A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'"Sonja Ständer, Andreas Pinter, Firas G Hougeir, et al.
European Journal of Medicinal Chemistry|October 3, 2006
High selective leishmanicidal activity of 3-hydroxy-2-methylene-3-(4-bromophenyl)propanenitrile and analogous compoundsR O M A de Souza, V L P Pereira, M F Muzitano, et al.
The British Journal of Dermatology|March 20, 2014
Treatment of port wine stains with pulsed dye laser and topical timolol: a multicenter randomized controlled trialT Passeron, A Maza, E Fontas, et al.
Annals of Nuclear Medicine|June 3, 2016
(18)F-FDG uptake by rectal cancer is similar in mucinous and nonmucinous histological subtypesDalton A Dos Anjos, Angelita Habr-Gama, Bruna B Vailati, et al.
Acta Dermato-Venereologica|October 7, 2021
Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic DermatitisJonathan I Silverberg, Eric L Simpson, Mark Boguniewicz, et al.
The British Journal of Dermatology|February 6, 2019
Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trialsA Blauvelt, D Rosmarin, T Bieber, et al.
Pageof 73

Showing results (561-570 of 724) with videos related to

Sort By:
Pageof 73
The Journal of Dermatological Treatment|April 30, 2020
Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trialsS Barbarot, A Wollenberg, J I Silverberg, et al.
Acta Dermato-Venereologica|May 27, 2021
Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant UseMette Deleuran, Danielle Marcoux, Marjolein S Bruin-Weller, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 4, 2025
Dupilumab improves quality of life assessed by the Quality of Life in Hand Eczema QuestionnaireEric L Simpson, Marie-Louise A Schuttelaar, Sonja Molin, et al.
Dermatology and Therapy|July 11, 2025
Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment ComparisonSonja Ständer, Andreas Pinter, Firas G Hougeir, et al.
Dermatology and Therapy|December 29, 2025
A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'"Sonja Ständer, Andreas Pinter, Firas G Hougeir, et al.
European Journal of Medicinal Chemistry|October 3, 2006
High selective leishmanicidal activity of 3-hydroxy-2-methylene-3-(4-bromophenyl)propanenitrile and analogous compoundsR O M A de Souza, V L P Pereira, M F Muzitano, et al.
The British Journal of Dermatology|March 20, 2014
Treatment of port wine stains with pulsed dye laser and topical timolol: a multicenter randomized controlled trialT Passeron, A Maza, E Fontas, et al.
Annals of Nuclear Medicine|June 3, 2016
(18)F-FDG uptake by rectal cancer is similar in mucinous and nonmucinous histological subtypesDalton A Dos Anjos, Angelita Habr-Gama, Bruna B Vailati, et al.
Acta Dermato-Venereologica|October 7, 2021
Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic DermatitisJonathan I Silverberg, Eric L Simpson, Mark Boguniewicz, et al.
The British Journal of Dermatology|February 6, 2019
Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trialsA Blauvelt, D Rosmarin, T Bieber, et al.
Pageof 73